Miguel A. Piris undertakes multidisciplinary investigations into Lymphoma and CD30 in his work. Miguel A. Piris conducts interdisciplinary study in the fields of Pathology and Differential diagnosis through his research. Miguel A. Piris performs multidisciplinary study in Differential diagnosis and Pathology in his work. His research on Genetics frequently connects to adjacent areas such as Aggressive lymphoma. In most of his Aggressive lymphoma studies, his work intersects topics such as Immunology. His work in Immunology is not limited to one particular discipline; it also encompasses T-cell lymphoma. He conducts interdisciplinary study in the fields of T-cell lymphoma and Cancer through his research. His Cancer study frequently draws connections to adjacent fields such as Suppressor. Suppressor connects with themes related to Genetics in his study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
Mario F Fraga;Esteban Ballestar;Ana Villar-Garea;Manuel Boix-Chornet.
Nature Genetics (2005)
International network of cancer genome projects
Thomas J. Hudson;Thomas J. Hudson;Warwick Anderson;Axel Aretz;Anna D. Barker.
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente;Magda Pinyol;Víctor Quesada;Laura Conde.
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
William W L Choi;Dennis D. Weisenburger;Timothy Charles Greiner;Miguel A. Piris.
Clinical Cancer Research (2009)
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'.
Andrés J. M. Ferreri;Elías Campo;John F. Seymour;Rein Willemze.
British Journal of Haematology (2004)
Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.
Tomás Álvaro;Marylène Lejeune;Ma Teresa Salvadó;Ramón Bosch.
Clinical Cancer Research (2005)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu;Zijun Y. Xu-Monette;Alexander Tzankov;Tina Green.
Cell cycle deregulation in B-cell lymphomas.
Margarita Sánchez-Beato;Abel Sánchez-Aguilera;Miguel A. Piris.
Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
Verònica Fernàndez;Olga Salamero;Blanca Espinet;Francesc Solé.
Cancer Research (2010)
Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.
Bosch F;López-Guillermo A;Campo E;Ribera Jm.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: